Abstract
Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| Journal | Modern Rheumatology |
| DOIs | |
| Publication status | Accepted/In press - Dec 22 2017 |
Fingerprint
Keywords
- Biologic agents
- DAS28-ESR
- juvenile idiopathic arthritis
- polyarticular type
- treat to target
ASJC Scopus subject areas
- Rheumatology
Cite this
Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis : A multi-institutional study in Japan. / Kubota, Tomohiro; Takei, Syuji; Shimizu, Masaki; Yasumura, Junko; Nakagishi, Yasuo; Kizawa, Toshitaka; Yashiro, Masato; Wakiguchi, Hiroyuki; Yamasaki, Yuichi; Kawano, Yoshifumi.
In: Modern Rheumatology, 22.12.2017, p. 1-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis
T2 - A multi-institutional study in Japan
AU - Kubota, Tomohiro
AU - Takei, Syuji
AU - Shimizu, Masaki
AU - Yasumura, Junko
AU - Nakagishi, Yasuo
AU - Kizawa, Toshitaka
AU - Yashiro, Masato
AU - Wakiguchi, Hiroyuki
AU - Yamasaki, Yuichi
AU - Kawano, Yoshifumi
PY - 2017/12/22
Y1 - 2017/12/22
N2 - Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.
AB - Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.
KW - Biologic agents
KW - DAS28-ESR
KW - juvenile idiopathic arthritis
KW - polyarticular type
KW - treat to target
UR - http://www.scopus.com/inward/record.url?scp=85039865192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039865192&partnerID=8YFLogxK
U2 - 10.1080/14397595.2017.1415628
DO - 10.1080/14397595.2017.1415628
M3 - Article
SP - 1
EP - 6
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
ER -